Logo image of KZIA

KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis

NASDAQ:KZIA - Nasdaq - US48669G2049 - ADR - Currency: USD

3.3  -0.24 (-6.77%)

After market: 3.29 -0.01 (-0.3%)

Fundamental Rating

1

Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 568 industry peers in the Biotechnology industry. KZIA may be in some trouble as it scores bad on both profitability and health. KZIA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KZIA has reported negative net income.
KZIA had a negative operating cash flow in the past year.
KZIA had negative earnings in each of the past 5 years.
KZIA had a negative operating cash flow in each of the past 5 years.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

KZIA has a worse Return On Assets (-124.06%) than 80.11% of its industry peers.
Industry RankSector Rank
ROA -124.06%
ROE N/A
ROIC N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

0

2. Health

2.1 Basic Checks

KZIA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KZIA has less shares outstanding
The debt/assets ratio for KZIA is higher compared to a year ago.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -11.81, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KZIA (-11.81) is worse than 76.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.81
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

KZIA has a Current Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
KZIA has a worse Current ratio (0.24) than 95.77% of its industry peers.
A Quick Ratio of 0.24 indicates that KZIA may have some problems paying its short term obligations.
The Quick ratio of KZIA (0.24) is worse than 95.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.24
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 92.01% over the past year.
KZIA shows a strong growth in Revenue. In the last year, the Revenue has grown by 10211.56%.
Measured over the past years, KZIA shows a very strong growth in Revenue. The Revenue has been growing by 87.69% on average per year.
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.78%
Revenue 1Y (TTM)10211.56%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -55.13% on average over the next years. This is quite bad
KZIA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.21% yearly.
EPS Next Y-47372.73%
EPS Next 2Y-1426.14%
EPS Next 3Y-465.76%
EPS Next 5Y-55.13%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y16.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 50M 100M 150M 200M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZIA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

KZIA's earnings are expected to decrease with -465.76% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1426.14%
EPS Next 3Y-465.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZIA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (4/17/2025, 8:00:02 PM)

After market: 3.29 -0.01 (-0.3%)

3.3

-0.24 (-6.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20
Earnings (Next)N/A N/A
Inst Owners13.93%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.44M
Analysts82.86
Price TargetN/A
Short Float %5.33%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-37242.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.25
EYN/A
EPS(NY)-3.38
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0.26
BVpS-1.14
TBVpS-2.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.24
Altman-Z -11.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.78%
EPS Next Y-47372.73%
EPS Next 2Y-1426.14%
EPS Next 3Y-465.76%
EPS Next 5Y-55.13%
Revenue 1Y (TTM)10211.56%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y16.21%
EBIT growth 1Y-13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.78%
OCF growth 3YN/A
OCF growth 5YN/A